医学教育

订阅

MedSci主页 / 所有栏目 / 医学教育

如何选题与评价选题的可行性？

2021-05-26 MedSci原创 MedSci原创

关注

如何选题与评价选题的可行性？

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022961, encodeId=040020229617f, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Jul 20 09:48:19 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641159, encodeId=9d911641159d2, content=<a href='/topic/show?id=053d948049e' target=_blank style='color:#2F92EE;'>#选题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94804, encryptionId=053d948049e, topicName=选题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723122754863, createdName=12498bd5m23暂无昵称, createdTime=Fri May 06 16:48:19 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444701, encodeId=658b1444e01cd, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri May 28 01:48:19 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2021-07-20 循证小兵

    #可行性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2022961, encodeId=040020229617f, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Jul 20 09:48:19 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641159, encodeId=9d911641159d2, content=<a href='/topic/show?id=053d948049e' target=_blank style='color:#2F92EE;'>#选题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94804, encryptionId=053d948049e, topicName=选题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723122754863, createdName=12498bd5m23暂无昵称, createdTime=Fri May 06 16:48:19 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444701, encodeId=658b1444e01cd, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri May 28 01:48:19 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2022-05-06 12498bd5m23暂无昵称

    #选题#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2022961, encodeId=040020229617f, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Jul 20 09:48:19 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641159, encodeId=9d911641159d2, content=<a href='/topic/show?id=053d948049e' target=_blank style='color:#2F92EE;'>#选题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94804, encryptionId=053d948049e, topicName=选题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723122754863, createdName=12498bd5m23暂无昵称, createdTime=Fri May 06 16:48:19 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444701, encodeId=658b1444e01cd, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri May 28 01:48:19 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2021-05-28 huagfeg

    #评价#

    0